Physician profile
Anna Donovan
NPI 1346779253
$2,702.44
in general payments reported to CMS, 2019-2025
20 companies · $737 in 2025
The $737 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $182 · 2023: $561 · 2024: $902 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,100 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.48 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.81 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $422.02 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $281.75 | 2022-2024 | Sotyktu |
| Allergan, INC. | $254.89 | 2021-2022 | |
| Janssen Biotech, INC. | $229.17 | 2023-2025 | Tremfya, Simponi, Remicade |
| Novartis Pharmaceuticals Corporation | $193.05 | 2021-2025 | |
| Incyte Corporation | $173.47 | 2021-2025 | Opzelura |
| Pfizer INC. | $90.97 | 2022-2024 | |
| Lilly USA, LLC | $86.39 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $82.15 | 2023-2025 | Bimzelx |
| Almirall LLC | $67.39 | 2022-2025 | Klisyri |
| Arcutis Biotherapeutics, INC. | $51.48 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $41.50 | 2023-2025 | Anzupgo, Adbry |
| Verrica Pharmaceuticals INC. | $37.52 | 2023-2024 | Ycanth |
| Biofrontera INC. | $33.30 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.07 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.17 | 2025 | Libtayo |
| Organon LLC | $22.46 | 2025 | Vtama |
| Dermavant Sciences, INC. | $17.80 | 2024 | Vtama |
| Organogenesis INC. | $16.08 | 2025 | Novachor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.